Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4342459 | 0.93 | MAPK14 (0.82) | MAPK14MAPK9MAPK10MAPK11 | |
| SCHEMBL4333445 | 0.92 | MAPK14 (0.59) | MAPK14MAPK1HTTGLATSHR | |
| SCHEMBL4329415 | 0.88 | MAPK14 (0.71) | MAPK14MAPK1HTTTSHRKMT2A | |
| SCHEMBL4332789 | 0.87 | MAPK14 (0.63) | MAPK14MAPK1HTTGLATSHR | |
| SCHEMBL4332754 | 0.86 | MAPK14 (0.61) | MAPK14HSP90AA1MAPK9MAPK10MAPK11 | |
| SCHEMBL4341269 | 0.86 | MAPK14 (0.58) | MAPK14MAPK1HTTHSP90AA1TSHR | |
| SCHEMBL4346666 | 0.86 | MAPK14 (0.54) | MAPK14HSP90AA1MAPK9MAPK10MAPK11 | |
| SCHEMBL4327702 | 0.85 | MAPK14 (0.70) | MAPK14HSP90AA1MAPK9MAPK10MAPK11 | |
| SCHEMBL4339271 | 0.84 | MAPK14 (0.52) | MAPK14HSP90AA1MAPK9MAPK10MAPK11 | |
| SCHEMBL4330144 | 0.83 | MAPK14 (0.59) | MAPK14HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036905-B1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MAPK14 43/4885MAPK1 2/4885HTT 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.